@article{01JHF5PB1NEED5MVD1H8W5E7TN,
  abstract     = {{Portal hypertension (PH) can cause severe complications in patients with advanced chronic liver disease (aCLD). The pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist lanifibranor reduces portal pressure in preclinical models of aCLD. Since the effect on PH might be secondary to fibrosis improvement, we investigated the effect of lanifibranor on PH, hepatic and splanchnic angiogenesis in mouse models of fibrotic and prehepatic non-fibrotic PH. Mice with fibrotic PH (common bile duct ligation; CBDL) and prehepatic PH (partial portal vein ligation; PPVL) received daily lanifibranor/vehicle for 14 or 7 days, respectively. Hemodynamics, serum, hepatic and mesenteric histology, and hepatic, mesenteric and liver sinusoidal endothelial cells (LSEC) gene expression levels were analyzed. Vascular corrosion casts of the venous mesenteric and hepatic vasculature were analyzed using scanning electron microscopy and µCT. Portal pressure was increased in CBDL mice. Lanifibranor treatment demonstrated a dose-dependent trend towards decreasing the elevated portal pressure, and reduced fibrosis. Hepatic mRNA levels of inflammatory, fibrotic and angiogenic markers were significantly downregulated in lanifibranor-treated CBDL mice. LSEC dysfunction was improved by lanifibranor. Compared to CBDL mice, portal pressure was more extensively elevated in PPVL mice, which was significantly reduced by lanifibranor. Superior mesenteric artery blood flow, which was increased in vehicle-treated PPVL mice, tended to decrease by lanifibranor. The expansion of the mesenteric vasculature and mesenteric protein level of angiogenetic markers in PPVL mice were reduced after lanifibranor. In conclusion, lanifibranor improves PH, independently from fibrosis reduction, potentially through reducing the venous mesenteric vasculature expansion and intrahepatic angiogenesis, and ameliorating LSEC function.}},
  articleno    = {{117826}},
  author       = {{Heldens, Anneleen and Casteleyn, Christophe and Onghena, Louis and Antwi, Milton Boaheng and Neyt, Sara and Descamps, Benedicte and Vanhove, Christian and Verhelst, Xavier and Raevens, Sarah and Van Vlierberghe, Hans and Devisscher, Lindsey and De Bruyne, Ruth and Junien, Jean-Louis and Wettstein, Guillaume and Geerts, Anja and Lefere, Sander}},
  issn         = {{0753-3322}},
  journal      = {{BIOMEDICINE & PHARMACOTHERAPY}},
  language     = {{eng}},
  pages        = {{12}},
  title        = {{The pan-PPAR agonist lanifibranor reduces portal pressure independent of fibrosis reduction through the splanchnic vasculature}},
  url          = {{http://doi.org/10.1016/j.biopha.2025.117826}},
  volume       = {{183}},
  year         = {{2025}},
}

Altmetric

View in Altmetric